NervGen Doses First Patient in Phase 3 NVG-291 Trial
NervGen has dosed the first participant in the registrational RESTORE study of NVG-291. Topline results are expected in the first half of 2028.
- published
- in the api
- on the website
on the website stories appear 15 minutes after publication, in the api at once. connect the api →
what happened
TradingView, citing a NervGen press release distributed through GlobeNewswire, reported that the company dosed the first participant in RESTORE. The Phase 3 registrational study is evaluating NVG-291 in patients with chronic cervical spinal cord injury and motor-incomplete impairment.
Enrollment is expected to finish in the second half of 2027, with topline results targeted for the first half of 2028. The trial is planned to include about 150 participants in the United States and Canada. Hand function is the primary endpoint. NVG-291 also has FDA Fast Track designation.
why it matters
The first patient dose moves the program into a late-stage registrational trial after earlier Phase 1b/2a work. The pace of enrollment and results on the hand-function endpoint will be key milestones through the first half of 2028.
instruments
sources
- NervGen (NGEN) Doses First Patient in Phase 3 RESTORE SCI Trial — TradingView, 12 October 2026 at 11:15 UTC
prepared by the newsmetry newsroom with ai assistance from the sources listed below. not investment advice.
on the website stories appear 15 minutes after publication, in the api at once.
get stories in real time ↗